EyeGene, Inc. - Product Pipeline Review - 2015

Published: October 2015
No. of Pages: 25
   

Global Markets Direct’s, ‘EyeGene, Inc. Product Pipeline Review 2015’, provides an overview of the EyeGene, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of EyeGene, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides brief overview of EyeGene, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of EyeGene, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the EyeGene, Inc.’s pipeline products

Reasons to buy


  • Evaluate EyeGene, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of EyeGene, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the EyeGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of EyeGene, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of EyeGene, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of EyeGene, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

EyeGene, Inc. - Product Pipeline Review - 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
EyeGene, Inc. Snapshot 5
EyeGene, Inc. Overview 5
Key Information 5
Key Facts 5
EyeGene, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
EyeGene, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
EyeGene, Inc. - Pipeline Products Glance 10
EyeGene, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
EyeGene, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
EyeGene, Inc. - Drug Profiles 13
EG-Mirotin 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
EG-Decorin 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
EG-HPV 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
EGS-001 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
EyeGene, Inc. - Pipeline Analysis 18
EyeGene, Inc. - Pipeline Products by Target 18
EyeGene, Inc. - Pipeline Products by Route of Administration 19
EyeGene, Inc. - Pipeline Products by Molecule Type 20
EyeGene, Inc. - Pipeline Products by Mechanism of Action 21
EyeGene, Inc. - Dormant Projects 22
EyeGene, Inc. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

List of Tables

EyeGene, Inc., Key Information 5
EyeGene, Inc., Key Facts 5
EyeGene, Inc. - Pipeline by Indication, 2015 7
EyeGene, Inc. - Pipeline by Stage of Development, 2015 8
EyeGene, Inc. - Monotherapy Products in Pipeline, 2015 9
EyeGene, Inc. - Phase II, 2015 10
EyeGene, Inc. - Phase I, 2015 11
EyeGene, Inc. - Preclinical, 2015 12
EyeGene, Inc. - Pipeline by Target, 2015 18
EyeGene, Inc. - Pipeline by Route of Administration, 2015 19
EyeGene, Inc. - Pipeline by Molecule Type, 2015 20
EyeGene, Inc. - Pipeline Products by Mechanism of Action, 2015 21
EyeGene, Inc. - Dormant Developmental Projects,2015 22

List of Figures

EyeGene, Inc. - Pipeline by Top 10 Indication, 2015 7
EyeGene, Inc. - Pipeline by Stage of Development, 2015 8
EyeGene, Inc. - Monotherapy Products in Pipeline, 2015 9
EyeGene, Inc. - Pipeline by Top 10 Route of Administration, 2015 19
EyeGene, Inc. - Pipeline by Top 10 Molecule Type, 2015 20

Published By: Global Markets Direct
Product Code: Global Markets Direct13285


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: